- ￥6768
- AntibodySystem
- 0.31-5 μg/mL
- 0.156 μg/ml
- KDB95803
- France
- 2025年07月11日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
999
- 供应商：
AntibodySystem
- 检测范围：
0.31-5 μg/mL
- 检测方法：
Colorimetric
- 应用：
ELISA
- 标记物：
HRP
- 样本：
Plasma, Serum
- 灵敏度：
0.156 μg/ml
- 规格：
96T
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 检测方法 | Colorimetric |
| 精准度 |
CV<20% |
| 样本类型 | Plasma, Serum |
| 实验类型 | Quantitative |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 背景 | Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25 blockade reduces IL-2 consumption by effector T cells, it increases IL-2 bioavailability allowing for greater interaction with the intermediate-affinity IL-2R, and therefore drives the expansion of CD56bright natural killer (NK) cells. Furthermore, there appears to be a direct correlation between CD56bright NK cell expansion and DAC HYP efficacy in reducing relapses and MRI evidence of disease activity in patients with RMS in phase II and phase III double-blind, placebo- and active comparator-controlled trials. Therapeutic efficacy was maintained during open-label extension studies. However, treatment was associated with an increased risk of rare adverse events, including cutaneous inflammation, autoimmune hepatitis, central nervous system Drug Reaction with Eosinophilia Systemic Symptoms (DRESS) syndrome, and autoimmune Glial Fibrillary Acidic Protein (GFAP) alpha immunoglobulin-associated encephalitis. As a result, DAC HYP was removed from clinical use in 2018. The lingering importance of DAC is that its use led to a deeper understanding of the underappreciated role of innate immunity in the potential treatment of autoimmune disease. |
| 别名 | BIIB019, DAC HYP, CAS: 152923-56-3 |
| 运输 | 2-8 ℃ |
| 备注 | For Research Use Only. |
AntibodySystem Laboratories SAS was established in 2019 in France as an independent brand entity focused on the research, development, and production of protein and antibody reagents in the life sciences field. Our mission is to provide high-quality protein and antibody products to life science researchers worldwide. AntibodySystem's extensive product range includes traditional polyclonal antibodies, classic housekeeping antibodies, tag antibodies, high-activity proteins, in vivo functional antibodies, low-background flow cytometry antibodies, high-specificity nanobodies, specialized small molecule antibodies, premium phospho-specific antibodies, DNA/RNA antibodies, PEG antibodies, and more—spanning over ten product series.
Currently, AntibodySystem's product lines cover multiple research areas, including 48 types of viruses and superbugs, parasites, tumors, Alzheimer's disease, Parkinson's disease, hypersensitivity and allergic reactions, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
